Drugs acting on mast cells functions: A cell biological perspective

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 4, 2010, Pages 214-228

  Bacci, Stefano ^a   Romagnoli, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allergy; Asthma; Atopic dermatitis; Histochemistry; Mastocytosis; Receptors; Signal transduction

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA INTERFERON; ANANDAMIDE; APC 2059; ATRACURIUM; BUPRENORPHINE; CARBON MONOXIDE; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; FC RECEPTOR IIB; GLUCOCORTICOID; HYBRID PROTEIN; IMATINIB; LIGAND; MK 57167; MONOCLONAL ANTIBODY; MORPHINE; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; NEDOCROMIL SODIUM; NIMESULIDE; NITRIC OXIDE; NOLADIN ETHER; OMALIZUMAB; TACROLIMUS; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECURONIUM; VELIFLAPON; ZAFIRLUKAST;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ARTHRITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL HETEROGENEITY; CHRONIC LEUKEMIA; HUMAN; HYPERTROPHIC SCAR; IMMUNOPATHOLOGY; INFECTION; KELOID; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOSIS; NEOPLASM; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CROSS LINKING;

EID: 79751475696     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810793358813     Document Type: Article

References (238)

1. Ehrlich, P. Beiträge zur theorie und praxis der Histologischen Färbung. Thesis, Leipzig, 1878.
2. Bacci, S.; Bonelli, A.; Romagnoli, P. In cell movement: new research trends; Abreu, T.; Silva, G. Eds.; Nova Science Publishers: Hauppage, NY, 2009; pp. 81-121.
3. A.M. New aspect of mast cell biology. Int. Arch. Allergy Immunol., 1997, 114, 1-9.
4. Crivellato, E.; Ribatti, D.; Mallardi, F.; Beltrami, C.A. Granule changes of human and murine endocrine cells in the gastrointestinal epithelia are characteristic of piecemeal degranulation. Anat. Rec., 2002, 268, 353-359.
5. Crivellato, E.; Beltrami, C.A.; Mallardi, F.; Ribatti, D. The mast cell: an active participant or an innocent bystander? Histol. Histopathol., 2004, 19, 259-270.
6. Crivellato, E.; Nico, B.; Berteli, E; Nussdorfer, G.G.; Ribatti, D. Densecore granules in neuroendocrine cells and neurons release their secretory constituents by piecemeal degranulation. Int. J. Mol. Med., 2006, 18, 1037-1046.
7. Melo, R.C.; Spencer, L.A.; Dvorak, A.M.; Weller, P.F. Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins. J. Leukoc. Biol., 2008, 83, 229-236.
8. Cutz, E.; Chan, W.; Track, N.S.; Goth, A.; Said, S.I. Release of vasointestinal polypeptide in mast cells by histamine liberators. Nature, 1978, 275, 661-662.
9. Goetzl, E.J.; Sreedharan, S.P.; Turck, C.W. Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells. J. Biol. Chem., 1988, 263, 9083-9086.
10. Bacci, S.; Faussone-Pellegrini, M.S.; Mayer, B.; Romagnoli, P. Distribution of mast cells in human ileocecal region. Dig. Dis. Sci., 1995, 40, 357-365.
11. Mekori, Y.A.; Metcalfe, D.D. Mast cell-T cell interactions. J. Allergy Clin. Immunol., 1999, 104, 517-523.
12. Castells, M.C. Mast cell mediators in allergic inflammation and mastocytosis. Immunol. Allergy Clin. N. Am., 2006, 26, 465-485.
13. Theoharides, T.C.; Kempuraj, D.; Tagen, M.; Conti, P.; Kalogeromitros, D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev., 2007, 217, 65-78.
14. Dvorak, A.M.; Morgan, E.S.; Weller, P.F. RNA is closely associated with human mast cell lipid bodies. Histol. Histopathol., 2003, 3, 943-968.
15. Masini, E.; Salvemini, D.; Pistelli, A.; Mannaioni, P.F.; Vane, J.R. Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine. Agents Actions, 1991, 33, 61-63.
16. Forsythe, P.; Gilchrist, M.; Kulka, M.; Befus, A.D. Mast cells and nitric oxide: control of production, mechanisms of response. Int. Immunopharmacol., 2001, 8, 1525-1541.
17. Bacci, S.; Arbi-Riccardi, R.; Mayer, B.; Rumio, C.; Borghi-Cirri, M.B. Localization of nitric oxide synthase immunoreactivity in mast cells of human nasal mucosa. Histochemistry, 1994, 102, 89-92.
18. Metcalfe, D.D.; Baram, D.; Mekori, Y.A. Mast cells. Physiol. Rev., 1997, 77, 1033-1079.
19. Irani, A.M.; Bradford, T.R.; Kepley, C.L.; Schechter, N.M.; Schwartz, L.B. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and antichymase antibodies. J. Histochem. Cytochem., 1989, 37, 1509-1515.
20. Bacci, S.; Innocenti, S.; Benci, M. Mast cells and skin tumors. Skin Cancer, 1992, 7, 217-229.
21. Bradding, P.; Feather, I.H.; Wilson, S.; Holgate S.T., Howarth P.H. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am. J. Respir. Crit. Care Med., 1995, 151, 1900-1906.
22. Ghannadan, M.; Baghestanian, M.; Wimazal, F.; Eisenmenger, M.; Latal, D.; Kargül, G.; Walchshofer, S.; Sillaber, C.; Lechner, K.; Valent, P. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J. Invest. Dermatol., 1998, 151, 689-695.
23. Puxeddu, I.; Piliponsky, A.M.; Bachelet, I.; Levi-Schaffer, F. Mast cells in allergy and beyond. Int. J. Biochem. Cell. Biol., 2003, 35, 1601-1607.
24. Weidner, N.; Austen, K.F. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol. Res. Pract., 1993, 189, 156-162.
25. Li, L.; Meng, X.W.; Krilis, S.A. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand. J. Immunol., 1996, 156, 4839-4844.
26. Oskeritzian, C.A.; Zhao, W.; Min, H.K.; Xia, H.Z.; Pozez, A.; Kiev, J.; Schwartz, L.B. Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. J. Allergy Clin. Immunol., 2005, 115, 1162-1168.
27. Gruber, B.L.; Schwartz, L.B.; Ramamurthy, N.S.; Irani, A.M.; Marchese, M.J. Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J. Immunol., 1988, 140, 3936-3942.
28. Irani, A.M.; Craig, S.S.; DeBlois, G.; Elson, C.O.; Schechter, N.M; Schwartz, L.B. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J. Immunol., 1987, 138, 4381-4386.
29. Friend, D.S; Ghildyal, N.; Austen, K.F.; Gurish, M.F.; Matsumoto, R.; Stevens, R.L. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J. Cell. Biol., 1996, 135, 279-290.
30. Sheen, C.H.; Schleimer, R.P.; Kulka, M. Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy, 2007, 62, 532-538.
31. Palomäki, V.A.; Laitinen, J.T. The basic secretagogue compound 48/80 activates G proteins indirectly via stimulation of phospholipase Dlysophosphatidic acid receptor axis and 5-HT1A receptors in rat brain sections. Br. J. Pharmacol., 2006, 147, 596-606.
32. Tatemoto, K.; Nozaki, Y.; Tsuda, R.; Konno, S.; Tomura, K.; Furono, M.; Ogasawara, H.; Taylor, S.M.; Finch, A.M.; Heron, A.E.; Brown, L.C.; Florin, T.H. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem. Biophys. Res. Commun., 2006, 349, 1322-1328.
33. Malaviya, R.; Abraham, S.N. Mast cell modulation of immune responses to bacteria. Immunol. Rev., 2001a, 179, 16-24.
34. Malaviya, R.; Navara, C.; Uckun, F.M. Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. Immunity, 2001b, 15, 313-321.
35. Ketavarapu, J.M.; Rodriguez, A.R.; Yu, J.J.; Cong, Y.; Murthy, A.K.; Forsthuber, T.G.; Guentzel, M.N.; Klose, K.E.; Berton, M.T.; Arulanandam, B.P. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc. Natl. Acad. Sci., 2008, 105, 9313-9318.
36. Sutherland, R.E.; Olsen, J.S.; McKinstry, A.; Villalta, S.A.; Wolters, P.J. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J. Immunol., 2008, 181, 5598-5605.
37. Yamasaki, S.; Saito, T. Progress in allergy signal research on mast cells: signal regulation of multiple mast cell responses through FcepsilonRI. J. Pharmacol. Sci., 2008, 106, 336-340.
38. Grochowy, G.; Hermiston, M.L.; Kuhny, M.; Weiss, A.; Huber, M. Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems. Cell Signal., 2009, 21, 1277-1286.
39. Gilfillan, A.M.; Tkaczyk, C. Integrated signalling pathways for mastcell activation. Nature, 2006, 6, 218-230.
40. Swindle, E.J.; Coleman, J.W.; DeLeo, F.R.; Metcalfe, D.D. FcepsilonRI- and Fcgamma receptor-mediated production of reactive oxygen species by mast cells is lipoxygenase- and cyclooxygenasedependent and NADPH oxidase-independent. J. Immunol., 2007, 179, 7059-7071.
41. Kuehn, H.S.; Swindle, E.J.; Kim, M.S.; Beaven, M.A.; Metcalfe, D.D.; Gilfillan, A.M. The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. J. Immunol., 2008, 181, 7706-7712.
42. Marone, G.; Genovese, A.; Granata, F.; Forte, V.; Detoraki, A.; de Paulis, A.; Triggiani, M. Pharmacological modulation of human mast cells and basophils. Clin. Exp. Allergy, 2002, 32, 1682-1689.
43. Grosman, N. Comparison of the influence of NSAIDs with different COX-selectivity on histamine release from mast cells isolated from naïve and sensitized rats. Int. Immunopharmacol., 2007, 7, 532-540.
44. Parravicini, V.; Gadina, M.; Kovarova, M.; Odom, S.; Gonzalez- Espinosa, C.; Furumoto, Y.; Saitoh, S.; Samelson, L.E.; O'Shea, J.J.; Rivera, J. Fyn kinase initiates complementary signals required for IgEdependent mast cell degranulation. Nat. Immunol., 2002, 3, 741-748.
45. Kambayashi, T.; Koretzky, G.A. Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J. Allergy Clin. Immunol., 2007, 119, 544-552.
46. Sim, A.T.; Ludowyke, R.I.; Verrills, N.M. Mast cell function: regulation of degranulation by serine/threonine phosphatases. Pharmacol. Ther., 2006, 112, 425-439.
47. Davis, B.J.; Flanagan, B.F.; Gilfillan, A.M.; Metcalfe, D.D.; Coleman, J.W. Nitric oxide inhibits IgE-dependent cytokine production and Fos and Jun activation in mast cells. J. Immunol., 2004, 173, 6914-6920.
48. Inoue, T.; Suzuki, Y.; Yoshimaru, T.; Ra, C. Nitric oxide protects mast cells from activation-induced cell death: the role of the phosphatidylinositol-3 kinase-Akt-endothelial nitric oxide synthase pathway. J. Leukoc. Biol., 2008, 83, 1218-1229.
49. Inoue, T.; Suzuki, Y.; Yoshimaru, T.; Ra, C. Nitric Oxide positively regulates Ag (I)-induced Ca(2+) influx and mast cell activation: role of a Nitric Oxide Synthase-independent pathway. J. Leukoc. Biol., 2009, 86, 1365-1375.
50. Jeong, H.J.; Lee, S.A.; Moon, P.D.; Na, H.J.; Park, R.K.; Um, J.Y.; Kim, H.M.; Hong, S.H. Alginic acid has anti-anaphylactic effects and inhibits inflammatory cytokine expression via suppression of nuclear factor-kappaB activation. Clin. Exp. Allergy, 2006, 36, 785-794.
51. Kitaura, J.; Asai, K.; Maeda-Yamamoto, M.; Kawakami, Y.; Kikkawa, U.; Kawakami, T. Akt-dependent cytokine production in mast cells. J. Exp. Med, 2000, 192, 729-740.
52. Rasheed, Z.; Aktar, N.; Khan, K.A.; Haggi, T.M. Butrin, isobutrin, and butein from medicinal plant Butea monosperma selectively inhibit nuclear factor-kappaB in activated human mast cells: suppression of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. J. Pharmacol. Exp. Ther., 2010, 333, 354-363.
53. Malaviya, R.; Chen, C.L.; Navara, C.; Malaviya, R.; Liu, X.P.; Keenan, M.; Waurzyniak, B.; Uckun, F.M. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther., 2000, 295, 912-926.
54. Irie-Sasaki, J.; Sasaki, T.; Matsumoto, W.; Opavsky, A.; Cheng, M.; Welstead, G.; Griffiths, E.; Krawczyk, C.; Richardson, C.D.; Aitken, K.; Iscove, N.; Koretzky, G.; Johnson, P.; Liu, P.; Rothstein, D.M.; Penninger, J.M. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature, 2001, 409, 349-354.
55. Lesley, J.; Himan, R.; Kincade, P.W. CD44 and its interaction with extracellular matrix. Adv. Immunol., 1993, 54, 271-335.
56. Takano, H.; Nakazawa, S.; Shirata, N.; Tamba, S.; Furuta, K.; Tsuchiya, S.; Morimoto, K.; Itano, N.; Irie, A.; Ichikawa, A.; Kimata, K.; Nakayama, K.; Sugimoto, Y.; Tanaka, S. Involvement of CD44 in mast cell proliferation during terminal differentiation. Lab. Invest., 2009, 89, 446-455.
57. Kim, Y.; Lee, Y.S.; Hahn, J.H.; Choe, J.; Kwon, H.J.; Ro, J.Y.; Jeoung, D. Hyaluronic acid targets CD44 and inhibits FcepsilonRI signaling involving PKCdelta, Rac1, ROS, and MAPK to exert anti-allergic effect. Mol. Immunol., 2008, 45, 2537-2547.
58. Bochner, B.S.; Schleimer, R.P. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol. Rev., 2001, 179, 5-15.
59. Bochner, B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy, 2009, 39, 317-324.
60. Feng, C.; Beller, E.M.; Bagga, S.; Boyce, J.A. Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses. Blood, 2006, 107, 3243-3250.
61. Kay, L.J.; Yeo, W.W.; Peachell, P.T. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br. J. Pharmacol., 2006, 147, 707-713.
62. Weston, M.C.; Peachell, P.T. Regulation of human mast cell and basophil function by cAMP. Gen. Pharmacol., 1998, 31, 715-719.
63. Cao, J.; Papadopoulou, N.; Kempuraj, D.; Boucher, W.S.; Sugimoto, K.; Cetrulo, C.L.; Theoharides, T.C. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J. Immunol., 2005, 174, 7665-7675.
64. Cao, J.; Cetrulo, C.L.; Theoharides, T.C. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogenactivated protein kinase pathway. Mol. Pharmacol., 2006, 69, 998-1006.
65. Kalesnikoff, J.; Galli, S.J. New developments in mast cell biology. Nat. Immunol., 2008, 9, 1215-1223.
66. Bradding, P. The role of the mast cell in asthma: a reassessment. Curr. Opin. Allergy Clin. Immunol., 2003, 3, 45-50.
67. Bradding, P.; Walls, A.F.; Holgate, S.T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol., 2006, 117, 1277-1284.
68. Da Silva, C.A.; Blay, F.; Israel-Biet, D.; Laval, A.M.; Glasser, N.; Pauli, G.; Frossard, N. Effect of glucocorticoids on stem cell factor expression in human asthmatic bronchi. Clin. Exp. Allergy, 2006, 36, 317-324.
69. Kassell, O.; Schmidlin, F.; Duvernelle, C.; Gasser, B.; Massard, G.; Frossard, N. Human bronchial smooth muscle cells in culture produce stem cell factor. Eur. Respir. J., 1999, 13, 951-954.
70. Kovanen, P.T. Mast cells: multipotent local effector cells in atherothrombosis. Immunol. Rev., 2007, 217, 105-122.
71. Bacci, S.; Romagnoli, P. Smooth muscle cells, dendritic cells and mast cells: complementary roles in atherosclerosis. International Atherosclerosis Society. Available from: http://www.athero.org/commentaries/comm857.asp (Accessed January 2009).
72. Kovanen, P.T.; Kaartinen, M.; Paavonen, T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation, 1995, 92, 1084-1088.
73. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation, 1996, 94, 2787-2792.
74. Artuc, M.; Hermes, B.; Steckelings, U.M; Grützkau, A.; Henz, B.M. Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp. Dermatol., 1999, 8, 1-16.
75. Baum, C.L.; Arpey, C.J. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol. Surg., 2005, 31, 674-686.
76. Weller, K.; Foitzik, K.; Paus, R.; Syska, W.; Maurer, M. Mast cells are required for normal healing of skin wounds in mice. FASEB J, 2006, 20, 2366-2368.
77. Baghestanian, M.; Hofbauer, R.; Kress, H.G.; Wojta, J.; Fabry, A.; Binder, B.R.; Kaun, C.; Müller, M.R.; Mehrabi, M.R.; Kapiotis, S.; Sengoelge, G.; Ghannadan, M.; Lechner, K.; Valent, P. Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF. Thromb. Haemost., 1997, 77, 577-584.
78. Bonelli, A.; Bacci, S.; Norelli, G.A. Affinity cytochemistry analysis of mast cells in skin lesions: a possible tool to assess the timing of lesions after death. Int. J. Legal Med., 2003, 117, 331-334.
79. Bacci, S.; Romagnoli, P.; Norelli, G.A.; Forestieri, A.L.; Bonelli, A. Early increase in TNF-alpha-containing mast cells in skin lesions. Int. J. Legal Med., 2006, 120, 138-142.
80. Trautmann, A.; Toksoy, A.; Engelhardt, E.; Bröcker, E.B.; Gillitzer, R. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. J. Pathol., 2000, 190, 100-106.
81. Gruber, B.L.; Marchese, M.J.; Kew, R. Transforming growth factorbeta 1 mediates mast cell chemotaxis. J. Immunol., 1994, 152, 5860-5867.
82. Levi-Schaffer, F.; Piliponsky, A.M. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol., 2003, 24, 158-161.
83. Xu, X.; Weksler-Zangen, S.; Pikarsky, A.; Pappo, O.; Wengrower, D.; Bischoff, S.C.; Pines, M.; Rivkind, A.; Goldin, E.; Levi-Schaffer, F. Mast cells involvement in the inflammation and fibrosis development of the TNBS-induced rat model of colitis. Scand. J. Gastroenterol., 2002, 37, 330-337.
84. Gruber, B.L. Mast cells in the pathogenesis of fibrosis. Curr. Rheumatol. Rep., 2003, 5, 147-153.
85. Gruber, B.L.; Kew, R.R.; Jelaska, A.; Marchese, M.J.; Garlick, J.; Ren, S.; Schwartz, L.B.; Korn, J.H. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol., 1997, 158, 2310-2317.
86. Benoist, C.; Mathis D. Mast cells in autoimmune disease. Nature, 2002, 26, 420, 875-878.
87. Zappulla, J.P.; Arock, M.; Mars, L.T.; Liblau, R.S. Mast cells: new targets for multiple sclerosis therapy? J. Neuroimmunol., 2002, 131, 5-20.
88. Olsson, N.; Ulfgren, A.K.; Nilsson, G. Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann. Rheum. Dis., 2001, 60, 187-193.
89. Maruotti, N.; Crivellato, E.; Cantatore, P.F.; Vacca, A.; Ribatti, D. Mast cells in rheumatoid arthritis. Clin. Rheumatol., 2007, 26, 1-4.
90. Kobayashi, Y.; Okunishi, H. Mast cells as a target of rheumatoid arthritis treatment. Jpn. J. Pharmacol., 2002, 90, 07-11.
91. Metcalfe, D.D. Mast cells and mastocytosis. Blood, 2008, 112, 946-956.
92. Kawakami, T.; Ando, T.; Kimura, M.; Wilson, S.B.; Kawakami, Y. Mast cells in atopic dermatitis. Curr. Opin. Immunol., 2009, 21, 666-678.
93. Vliagoftis, H.; Boucher, W.S.; Mak, L.L.; Theoharides, T.C. Inhibition of mast cell secretion by oxidation products of natural polyamines. Biochem. Pharmacol., 1992, 43, 2237-2245.
94. Vliagoftis, H.; Mak, L.; Boucher, W.; Theoharides, T.C. Dual effect of spermine on mast cell secretion exhibits different calcium and temperature requirements. Int. J. Immunopharmacol., 1999, 21, 547-559.
95. Theoharides, T.C.; Conti, P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol., 2004, 25, 235-241.
96. Levi-Shaffer, F.; Slovik, D.; Armetti, L.; Pickoltz, D.; Touitou, E. Activation and inhibition of mast cells degranulation affect their morphometric parameters. Life Sci., 2000, 66, 283-290.
97. Brightling, C.E.; Bradding, P.; Pavord, I.D.; Wardlaw, A.J. New insights into the role of the mast cell in asthma. Clin. Exp. Allergy, 2003, 33, 550-556.
98. Schramm, R.; Thorlacius, H. Neutrophil recruitment in mast celldependent inflammation: inhibitory mechanisms of glucocorticoids. Inflamm. Res., 2004, 53, 644-652.
99. Radley, H.G.; Grounds, M.D. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol. Dis., 2006, 2, 387-397.
100. Brown, J.M.; Wilson, T.M.; Metcalfe, D.D. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin. Exp. Allergy, 2007, 38, 4-18.
101. Nakamura, R.; Okunuki, H.; Ishida, S.; Saito, Y.; Teshima, R.; Sawada, J. Gene expression profiling of dexamethasone-treated RBL-2H3 cells: induction of anti-inflammatory molecules. J. Immunol. Lett., 2005, 98, 272-279.
102. Mygind, N.; Andersson, M. Topical glucocorticosteroids in rhinitis: mode of action. Acta Otolaryngol., 2006, 126, 676-678.
103. Kato, A.; Chustz R.T.; Ogasawara, T.; Kulka, M.; Saito, H.; Schleimer, R.P.; Matsumoto, K. Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J. Immunol, 2009, 182, 7233-7243.
104. Krishnaswamy, G.; Kelley, J.; Johnson, D.; Youngberg, G.; Stone, W.; Huang, SK.; Bieber, J.; Chi, D.S. The human mast cell: functions in physiology and disease. Front Biosci., 2001, 6, 1109-1127.
105. Belvisi, M.G. Regulation of inflammatory cell function by corticosteroids. Proc. Am. Thorac. Soc., 2004, 1, 207-214.
106. Crompton, R.; Clifton, V.L.; Bisits, A.T.; Read, M.A.; Smith, R.; Wright, I.M. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J. Clin. Endocrinol. Metab., 2003, 88, 5427-5432.
107. Lytinas, M.; Kempuraj, D.; Huang, M.; Boucher, W.; Esposito, P.; Theoharides, T.C. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol., 2003, 130, 224-231.
108. Ackermann, L.; Harvima, I.T. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res., 1998, 290: 353-359.
109. Schild, H. Histamine release in anaphylactic shock of isolated lungs of guinea pigs. Quart. J. Exp. Phisiol., 1937, 26, 165-179.
110. Gebhardt, T.; Gerhard, R.; Bedoui, S.; Erpenbeck, V.J.; Hoffman, M.W.; Manns, M.P.; Bishoff, S.C. beta2-Adrenoceptor-mediated suppression of human intestinal mast cell functions is caused by disruption of filamentous actin dynamics. Eur. J. Immunol., 2005, 35, 1124-1132.
111. Parikh, V.; Singh, M. Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection. Pharmacol. Res., 1999, 40, 129-137.
112. Coward, W.R.; Sagara, H.; Church, M.K. Asthma, adenosine, mast cells and theophylline. Clin. Exp. Allergy, 1998, 3, 42-46.
113. Weston, M.C.; Anderson, N.; Peachell, P.T. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br. J. Pharmacol., 1997, 121, 287-295.
114. Lewis, G.P.; Whittle, B.J.R. The inhibition of histamine release from rat peritoneal mast cells by non-steroid anti-inflammatory drugs and its reversal by calcium. Br. J. Pharmacol., 1977, 61, 229-235.
115. Gomes, J.C.; Pearce, F.L. Comparative studies on the effect of nonsteroidal anti-inflammatory drugs (NSAID) on histamine release from mast cells of the rat and guinea pig. Agents Actions, 1988, 24, 266-271.
116. N. Comparison of the influence of NSAIDS with different COX-selectivity on histamine release from mast cells isolated from naïve and sensitized rats. Int. Immunopharmacol., 2007, 7, 532-540.
117. Taylor, S.M.; Finch, A.M.; Heron, A.E.; Brown, L.C.; Florin, T.H. Reversibility of tachyphylaxis to C5A in guinea pig tissues, perfused human placental lobule, and umbilical artery. Inflammation, 1994, 18, 645-657.
118. Wong, W.S.; Bendele, A.M.; Fleisch, J.H. Pharmacologic evaluation of A23187-induced contractions of three distinct preparations of guinea pig lung parenchymal strips. J. Pharmacol. Exp. Ther., 1992, 260, 714-721.
119. Nasser, S.M.; Pfister, R.; Christie, P.E.; Sousa, A.R.; Barker, J.; Schmitz-Schumann, M.; Lee, T.H. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am. J. Respir. Crit. Care Med., 1996, 153, 90-96.
120. Bartee, E.; Mohamed, R.M.; McFadden, G.M. Tumor necrosis factor and interferon: cytokines in harmony. Curr. Opin. Microbiol., 2008, 11, 378-383.
121. Schernthaner, G.H.; Spanblochl, E.; Sperr, W.R.; Sillaber, C.; Sempper, H.; Jurecka, W.; Hagen, W.; Wolff, K.; Chott, A.; Lechner, K.; Valent, P. Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann. Hematol., 2000, 79, 660-666.
122. Schoeler, D.; Grützkau, A.; Henz, B.M.; Kuchler, J.; Kruger- Krasagakis, S. Interleukin-6 enhances whereas tumor necrosis factor alpha and interferons inhibit integrin expression and adhesion of human mast cells to extracellular matrix proteins. J. Invest. Dermatol., 2003, 120, 795-801.
123. Swieter, D.; Ghali, W.A.; Rimmer, C.; Befus, AD. Modulation of histamine secretion from rat and human mast cell subpopulations. Immunology, 1989, 66, 606-610.
124. Dalcik, D.; Irmak, M.K.; Ozcan, O.; Karaoz, E.; Oztas, E.; Dalicik, C. Response of the rat mucosal and connective tissue type mast cells to interferon-alpha. Acta Physiol. Pharmacol. Ther. Latinoam., 1996, 46, 11-21.
125. Bissonnette, E.Y.; Chin, B.; Befus, A.D. Interferons differentially regulate histamine and TNF-alpha in rat intestinal mucosal mast cells. Immunology, 1995, 86, 12-17.
126. Fujita, T., Kambe, N., Uchiyama, T., Hori, T. Type I interferons attenuate T cell activating functions of human mast cells by decreasing TNF-alpha production and OX40 ligand expression while increasing IL-10 production. J. Clin. Immunol., 2006, 26, 512-518.
127. Riccardi-Arbi, R.; Bacci, S.; Romagnoli, P.; Rucci, L. Interferon-alpha affects the tumour necrosis factor-alpha content of mast cells in human nasal mucosa. A pilot study in allergic patients. Ital. J. Anat. Embriol., 2004, 109, 115-122.
128. Hu, Z.Q.; Zhao, W.H.; Shimamura T. Regulation of mast cell development by inflammatory factors. Curr. Med. Chem., 2007, 14, 3044-3050.
129. Kambayashi, T.; Allenspach, E.J.; Chang, J.T.; Zou, T.; Shoag, J.E.; Reiner, S.L.; Caton, A.J.; Koretzky, G.A. Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J. Immunol., 2009, 182, 4686-4695.
130. Gilchrist, M.; Befus, A.D. Interferon-gamma regulates chemokine expression and release in the human mast cell line HMC1: role of nitric oxide. Immunology, 2008, 123, 209-217.
131. Hauswirth, A.W.; Simonitsch-Klupp, I.; Uffmann, M.; Koller, E.; Sperr, W.R.; Lechner K.; Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk. Res., 2004, 28, 249.
132. Pettigrew, H.D.; Teuber, S.S.; Kong, J.S.; Gershwin, M.E. Mold and human health: separating the wheat from the chaff. Clin. Rev. Allergy Immunol., 2010, 38, 148-155.
133. Juckett, G.; Hartman-Adams, H. Management of keloids and hypertrophic scars. Am. Fam. Physician, 2009, 80, 253.
134. Tredget, E.E.; Shankowsky H.A.; Pannu R.; Nedelec B.; Iwashina T.; Ghahary, A.; Taerum T.V.; Scott P.G. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg., 1998, 102, 1317-1328.
135. Wang, J.; Chen, H.; Shankowsky, H.A.; Scott, P.G.; Tredget, E.E. Improved scar in postburn patients following interferon-alpha2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor. J. Interferon Cytokine Res., 2008, 28, 423-434.
136. Borel, J.F. History of the discovery of cyclosporin and of its early pharmacological development. Wien. Klin. Wochenschr. 2002, 114, 433-437.
137. Borghi-Cirri, M.B.; Riccardi-Arbi, R.; Bacci, S.; Mori, M.; Pimpinelli, N.; Romagnoli, P.; Filipponi, F. Inhibited differentiation of Langerhans cells in the rat epidermis upon systemic treatment with cyclosporin A. Histol. Histopathol., 2001, 16, 107.
138. Broyd, H.; Koffer, A.; Assem, E.S. Effect of cyclosporin-A on secretion from intact and permeabilised mast cells. Inflamm. Res., 2005, 54, S07-S08.
139. Evans, D.J.; Cullinan, P.; Geddes, D.M. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane database of systematic reviews (Online), 2001, Avaialble from: http://www2.cochrane.org/reviews/en/ab002993.html
140. Gaga, M.; Zervas, E.; Grivas, S.; Castro, M.; Chanez, P. Evaluation and management of severe asthma. Curr. Med. Chem., 2007, 14, 1049-1059.
141. Kino, T.; Hatanaka, H.; Hashimoto, M.; Nishiyama, M.; Goto, T.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka, H. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot., 1987, 40, 1256-1265.
142. Hanifin, J.M.; Paller, A.S.; Eichenfield, L.; Clark, R.A.; Korman, N.; Weinstein, G.; Caro, I.; Jaracz, E.; Rico, M. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J. Am. Acad. Derm., 2005, 53, 186-194.
143. Di Gennaro, P.; Sestini, R.; Bacci, S.; Pacini, A.; Pinzani, P.; Domenici, L.; Toscano, A.; Massi, D.; Carli, P.; Genuardi, M.; Romagnoli, P. Tacrolimus causes reduced GLI1 expression and phenotypic changes in the TE 354.T basal cell carcinoma cell line. J. Dermatol. Sci., 2009, 54, 52-54.
144. Grützkau, A. Henz, B.M.; Kirchhof, L.; Luger, T.; Artuc, M. alpha- Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. Biochem. Biophys. Res. Commun., 2000, 278, 14-19.
145. Böhm, M.; Schiller, M.; Luger, T.A. Non-pigmentary actions of alphamelanocyte- stimulating hormone--lessons from the cutaneous melanocortin system. Cell. Mol. Biol., 2006, 52, 61-68.
146. Forsythe, P.; Ennis, M. Clinical consequences of mast cell heterogeneity. Inflamm. Res., 2000, 49, 147-154.
147. De Filippis, D.; D'Amico, A.; Iuvone, T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J. Neuroendocrinol., 2008, 20, 20-25.
148. Small-Howard, A.L.; Shimoda, L.M.; Adra, C.N.; Turner, H. Antiinflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem. J., 2005, 388, 465-473.
149. Maccarrone, M.; Fiorucci, L.; Erba, F.; Bari, M.; Finazzi-Agrò, A.; Ascoli, F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett., 2000, 468, 176-180.
150. Giannini, L.; Nistri, S.; Mastroianni, R.; Cinci, L.; Vannacci A.; Mariottini C.; Passani M.B.; Mannaioni P.F.; Bani D.; Masini E. Activation of cannabinoid receptors prevents antigen-induced asthmalike reaction in guinea pigs. J. Cell. Mol. Med., 2008, 12, 2381-2394.
151. Samson, M.T.; Small-Howard, A.; Shimoda, M.N.; Huberson-Koblan, M.; Stokes, J.A.; Turner, H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol., 2003, 170, 4953-4962.
152. Inoue, T.; Suzuki, Y.; Yoshimaru, T.; Ra, C. Nitric Oxide positively regulates Ag (I)-induced Ca(2+) influx and mast cell activation: role of a Nitric Oxide Synthase-independent pathway. J. Leukoc. Biol. 2009, 86, 1365-1375.
153. Moon, T.C.; Befus, A.D. Exogenous nitric oxide regulates cyclooxygenase-2 expression and prostaglandin D(2) generation through p38 MAPK in mouse bone marrow-derived mast cells. Free Rad. Biol. Med., 2008, 45, 780-788.
154. Coleman, J.W. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin. Exp. Immunol., 2002, 129, 4-10.
155. Sekar, Y.; Moon, T.C.; Muñoz, S.; Befus, A.D. Role of nitric oxide in mast cells: controversies, current knowledge, and future applications. Immunol. Res., 2005; 33, 223-239.
156. Navarro, A.; Boveris, A. Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. Adv. Drug Deliv. Rev., 2008, 13, 1534-1544.
157. Shimizu, Y.; Sakai, M.; Umemura, Y.; Ueda, H. Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J. Dermatol., 1997, 24, 80-87.
158. Gilchrist, M.; McCauley, S.D.; Befus, A.D. Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production. Blood, 2004, 104, 462-469.
159. Bacci, S.; Rucci, L.; Riccardi-Arbi, R., Borghi-Cirri, M.B. Colocalization of tumor necrosis factor-alpha and nitric oxide-synthase immunoreactivity in mast cell granules of nasal mucosa. Histol. Histopathol. 1998, 13, 1011-1014.
160. Bacci, S.; Pieri, L.; Buccoliero, A.M.; Bonelli, A.; Taddei, G.L.; Romagnoli, P. Smooth muscle cells, dendritic cells and mast cells are sources of TNFalpha and nitric oxide in human carotid artery atherosclerosis. Thromb. Res., 2008, 122, 657-667.
161. Otterbein, L.E; Bach, F.H.; Alam, J.; Soares, M.; Lu, H.T; Wysk, M.; Davis, R.J.; Flavell, R.A.; Choi, A.M. Carbon monoxide has antiinflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med., 2000, 6, 422-428.
162. Barañano, D.E.; Rao, M.; Ferris, D.C.; Snyder, S.H. Biliverdin reductase: A major physiologic cytoprotectant. Proc. Natl. Acad. Sci. USA, 2002, 99, 16093-16098.
163. Masini, E.; Vannacci, A.; Failli, P.; Mastroianni, R.; Giannini, L.; Vinci, M.C.; Uliva, C.; Motterlini, R.; Mannaioni, P.F. A carbon monoxidereleasing molecule (CORM-3) abrogates polymorphonuclear granulocyte-induced activation of endothelial cells and mast cells. FASEB J., 2008, 22, 3380-3388.
164. Takamiya, R.; Murakami, M.; Kajimura, M.; Goda, N.; Makino, N.; Takamiya, N.; Yamaguchi, T.; Ishimura, Y.; Hozumi, N.; Suematsu, M. Stabilization of mast cells by heme oxygenase-1: an anti-inflammatory role. Am. J. Phisiol. Heart Circ. Physiol., 2002, 283, 861-870.
165. D'Cruz, O.J.; Uckun, F.M. Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. Am. J. Reprod. Immunol., 2007, 58, 75-97.
166. Cetkovic-Cvrlje, M.; Tibbles, H.E. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Curr. Pharm. Des., 2004, 10, 1767-1784.
167. Daëron, M.; Malbec, O.; Latour, S.; Arock, M.; Fridman, W.H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Invest., 1995, 95, 577-585.
168. Malbec, O.; Fong, D.C.; Turner, M.; Tybulewicz, V.L.; Cambier, J.C.; Fridman, W.H.; Daëron, M. Fc epsilon receptor I-associated lyn dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J. Immunol., 1998, 160, 1647-1658.
169. Kepley, C.L.; Taghavi, S.; Mackay, G.; Zhu, D.; Morel, P.A.; Zhang, K.; Ryan, J.J.; Satin, L.S.; Zhang, M.; Pandolfi, P.P.; Saxon, A. Coaggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J. Biol. Chem., 2004, 279, 35139-35149.
170. Saxon, A.; Kepley, C.; Zhang, K. J. Accentuate the negative, eliminate the positive: engineering allergy therapeutics to block allergic reactivity through negative signaling. Allergy Clin. Immunol., 2008, 121, 320-325.
171. Akin, C.; Brochow, K.; D'Ambrosio, C.; Kirshenbaum, A.S.; Ma, Y.; Longley, B.J.; Metcalfe, D.D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol., 2003, 31, 686-692.
172. Ma, Y.; Zeng, S.; Metcalfe, D.D.; Akin, C.; Dimitrijevic, S.; Butterfield, J.H.; McMahon, G.; Longley, B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatorytype mutations. Blood, 2002, 99, 1741-1744.
173. Musto, P.; Falcone, A.; Sanpaolo, G.; Bodenizza, C.; Carella, A.M. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. Leuk. Res., 2004, 28, 421-422.
174. Pardanani, A.; Elliott, M.; Reeder T.; Li, C.Y.; Baxter, E.J.; Cross, N.C.; Tefferi, A. Imatinib for systemic mast-cell disease. Lancet, 2003; 362, 535-536.
175. Akin, C.; Brochow, K.; D'Ambrosio, C.; Kirshenbaum, A.S.; Ma, Y.; Longley, B.J.; Metcalfe, D.D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol., 2003, 31, 686-692.
176. Lahortiga, I.; Akin, C.; Cools, J.; Wilson, T.M.; Mentens, N.; Arthur, D.C.; Maric, I.; Noel, P.; Kocabas, C.; Marynen, P.; Lessin, L.S.; Wlodarska, I.; Robyn, J.; Metcalfe, D.D. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2- PDGFRB fusion. Haematologica, 2008, 93, 49-56.
177. Holgate, S.; Smith, N.; Massanari, M.; Jimenez, P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy, 2009, 64, 1728-1736.
178. Easthope, S.; Jarvis, B. Omalizumab. Drugs, 2001, 61, 253-260.
179. Plewako, H.; Arvidsson, M.; Petruson, K.; Oancea, I.; Holmberg, K.; Ädelroth, M.D.; Gustafsson, H.; Sandström, T.; Rak, S. The effect of omalizumab on nasal allergic inflammation. J. Allergy Clin. Immunol., 2002, 110, 68-71.
180. Ong, Y.E.; Menzies-Gow, A.; Barkans, J.; Benyahia, F.; Ou, T.T.; Ying, S.; Kay, A.B. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol., 2005, 116, 558-564.
181. Sicherer, S.H.; Leung, D.Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009. J. Allergy Clin. Immunol., 2010, 125, 85-97.
182. Kanaoka, Y.; Boyce, J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol., 2004, 173, 1503-1510.
183. Mellor, E.A.; Maekawa, A.; Austen, K.F.; Boyce, J.A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA, 2001, 98, 7964-7969.
184. Mellor, E.A; Austen, K.F; Boyce, J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp. Med., 2002, 195, 583-592.
185. Drazen, J.M.; Istrael, E.; O'Byrne, P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med., 1999, 340, 197-206.
186. Krawiec, M.E.; Wenzel, S.E. Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma. Exp. Opin. Pharmacother., 2001, 2, 47-65.
187. He, S.; Gaca, M.; Walls, A.F. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase. J. Pharmacol. Exp. Ther., 1998, 286, 289-297.
188. Berger, P.; Perng, D.W.; Thabrew, H.; Compton, S.J.; Cairns, J.A.; McEuen, A.R.; Marthan, R.; Tunon-De Lara, J.M.; Walls, A.F. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J. Appl. Physiol. 2001, 91, 1372-1379.
189. Cairns, J.A.; Walls, A.F. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J. Immunol., 1996, 156, 275-283.
190. Cairns, J.A., Walls, A.F. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest., 1997, 99, 1313-1321.
191. Krishna, M.T.; Chauhan, A.; Little, L.; Sampson, K.; Hawksworth, R.; Mant, T.; Djukanovic, R.; Lee, T.; Holgate S. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin. Immunol., 2001, 107, 1039-1045.
192. Tremaine, W.J.; Brzezinski, A.; Katz, J.A.; Wolf, D.C.; Fleming, T.J.; Mordenti, J.; Strenkoski-Nix, L.C.; Kurth, M.C. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment. Pharmacol. Ther, 2002, 16, 407-413.
193. Black, J. N. The role of mast cells in the pathophysiology of asthma. N. Engl. J. Med., 2002, 346, 1742-1743.
194. Cairns, J.A. Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders. Pulm. Pharmacol. Ther., 2005, 18, 55-66.
195. Trivedi, N.N., Caughey, G.H. Mast cell peptidases: chameleons of innate immunity and host defense. Am. J. Respir. Cell.Mol. Biol. 2010, 42, 257-267.
196. Kaymakcalan, Z.; Sakorafas, P.; Bose, S.; Scesney, S.; Xiong, L.; Hanzatian, D.K.; Salfeld, J.; Sasso, E.H. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol. 2009, 131, 308-316.
197. Atzeni, F.; Doria, A.; Carrabba, M.; Turiel, M.; Sarzi-Puttini, P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev., 2007, 6, 529-536.
198. Gordon, J.R.; Galli, S.J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature, 1990, 346, 274-276.
199. Woolhiser, M.R.; Okayama, Y.; Gilfillan, A.M.; Metcalfe, D.D. IgGdependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur. J. Immunol., 2001, 31, 3298-3307.
200. Okayama, Y.; Tkaczyk, C.; Metcalfe, D.D.; Gilfillan, A.M. Comparison of Fc epsilon RI- and Fc gamma RI-mediated degranulation and TNF-alpha synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for Fc gamma RI-induced degranulation. Eur. J. Immunol., 2003, 33, 1450-1459.
201. Tkaczyk, C.; Okayama, Y.; Metcalfe, D.D.; Gilfillan, A.M. Fcgamma receptors on mast cells: activatory and inhibitory regulation of mediator release. Int. Arch. Allergy Immunol., 2004, 133, 305-315.
202. Gebhardt, T.; Sellge, G.; Lorentz, A.; Raab, R.; Manns, M.P.; Bischoff, S.C. Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptordependent mediator release. Eur. J. Immunol., 2002, 32, 2308-2316.
203. Dahl, C.; Hoffmann, H.J.; Saito, H.; Schiøtz, P.O. Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy, 2004, 10, 1087-1096.
204. Hsieh, F.K.; Lam, B.K.; Penrose, J.F.; Austen, K.F.; Boyce, J.A. T helper cell type 2 cytokines coordinately regulate immunoglobulin Edependent cysteinyl leukotriene production by human cord bloodderived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J.Exp. Med., 2001, 193, 123-133.
205. Hide, M.; Yanase, Y.; Greaves, M. Cutaneous mast cell receptors. Dermatol. Clin., 2007, 25, 563-575.
206. Kinoshita, T.; Sawai, N.; Hidaka, E.; Yamashita, T.; Koike, K. Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+) cord blood cells. Blood, 1999, 94, 496-508.
207. Nickel, R.; Beck, L.A.; Stellato, C.; Schleimer, R.P. Chemokines and allergic disease. J. Allergy Clin. Immunol., 1999, 104, 723-742.
208. Romagnani, P.; De Paulis, A.; Beltrame, C.; Annunziato, F.; Dente, V.; Maggi, E.; Romagnani, S.; Marone, G. Tryptase-chymase doublepositive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol., 1999, 155, 1195-1204.
209. Welker, P.; Grabbe, J.; Zuberbier, T.; Grützkau, A.; Henz, B.M. GMCSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. Arch. Dermatol. Res., 2001, 293, 249-258.
210. Welker, P.; Grabbe, J.; Zuberbier, T.; Grützkau, A.; Henz, B.M. Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells. Arch. Dermatol. Res., 2001, 293, 249.
211. Kulka, M.; Sheen, C.H.; Tancowny, B.P.; Grammer, L.C.; Schleimer, R.P. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology, 2008, 123, 398-410.
212. Hashimoto, Y.; Arai, I.; Tanaka, M.; Nakaike, S. Prostaglandin D2 inhibits IgE-mediated scratching by suppressing histamine release from mast cells. J. Pharmacol. Sci., 2005, 98, 90-93.
213. Abdel-Majid, R.M.; Marshall, J.S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol., 2004, 172, 1227-1236.
214. Nakayama, T.; Mutsuga, N.; Yao, L.; Tosato, G. J. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. Leukoc. Biol., 2006, 79, 95-104.
215. Wang, X.S.; Lau, H.Y. Prostaglandin E potentiates the immunologically stimulated histamine release from human peripheral blood-derived mast cells through EP1/EP3 receptors. Allergy, 2006, 61, 503-506.
216. Mellor, E.A; Austen, K.F; Boyce, J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp. Med., 2002, 195, 583-592.
217. Paruchuri, S.; Jiang, Y.; Feng, C.; Francis, S.A.; Plutzky, J.; Boyce, J.A. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J. Biol. Chem., 2008, 283, 16477-16487.
218. Nilsson, G.; Metcalfe, D.D.; Taub D.D. Demonstration that plateletactivating factor is capable of activating mast cells and inducing a chemotactic response. Immunology, 2000, 99, 314-319.
219. Böhm, M.; Schiller, M.; Luger, T.A. Non-pigmentary actions of alphamelanocyte- stimulating hormone--lessons from the cutaneous melanocortin system. Cell. Mol. Biol., 2006, 52, 61-68.
220. Getting, S. J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol. Ther., 2006, 111, 1-15.
221. Yamaguchi, M.; Hirai, K.; Komiya, A.; Miyamasu, M.; Furumoto, Y.; Teshima, R.; Ohta, K.; Morita, Y.; Galli, S.J.; Ra, C.; Yamamoto, K. Regulation of mouse mast cell surface Fc epsilon RI expression by dexamethasone. Int. Immunol., 2001, 13, 843-851.
222. Barnes, J.A.; Singh, S.; Gomes, A.V. Protease activated receptors in cardiovascular function and disease. Mol. Cell. Biochem., 2004, 263, 227-239.
223. Scola, A.M.; Chong, L.K.; Chess-Williams, R.; Peachell, P.T. Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptormediated responses in mast cells. Br. J. Pharmacol., 2004, 143, 71-80.
224. Scola, A.M.; Chong, L.K.; Suvarna, S.K.; Chess-Williams, R.; Peachell, P.T. Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol. Br. J. Pharmacol., 2004, 141, 163-171.
225. Van der Kleij, H.P.; Ma, D.; Redegeld, F.A.; Kraneveld, A.D.; Nijkamp, F.P.; Bienenstock, J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J. Immunol., 2003, 171, 2074-2079.
226. Masini, E.; Blandina, P.; Mannaioni, P.F. Mast cell receptors controlling histamine release: influences on the mode of action of drugs used in the treatment of adverse drug reactions. Klin. Wechenschr., 1982, 60, 1031-1038.
227. Thurmond, R.L.; Desai, P.J.; Dunford, P.J.; Fung-Leung, W.P.; Hofstra, C.L.; Jiang, W.; Nguyen, S.; Riley, J.P.; Sun, S; Williams, K.N.; Edwards, J.P.; Karlsson, L. J. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Pharmacol. Exp. Ther., 2004, 309, 404-413.
228. Varga, C.; Horvath, K.; Berko, A.; Thurmond, R.L.; Dunford, P.J.; Whittle, B.J. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur. J. Pharmacol., 2005, 17, 130-138.
229. McCurdy, J.D.; Olynych, T.J.; Maher, L.H.; Marshall, J.S. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol., 2003, 170, 1625-1629.
230. Malaviya, R.; Georges, A. Regulation of mast cell-mediated innate immunity during early response to bacterial infection. Clin. Rev. Allergy Immunol., 2002, 22, 189.
231. Niyonsaba, F.; Someya, A.; Hirata, M.; Ogawa, H.; Nagaoka, I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol., 2001, 31, 1066-1075.
232. Niyonsaba, F.; Hirata, M.; Ogawa, H.; Nagaoka, I. Epithelial cellderived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells. Curr. Drug Targets Inflamm. Allergy, 2003, 2, 224-231.
233. Niyonsaba, F.; Iwabuchi, K.; Someya, A.; Hirata, M.; Matsuda, H.; Ogawa, H.; Nagaoka, I. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology, 2002, 106, 20-26.
234. Valent, P.; Bettelheim, P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol., 1992, 52, 333-423.
235. Ra, C.; Yasuda, M.; Yagita, H.; Okumura, K. Fibronectin receptor integrins are involved in mast cell activation. J Allergy Clin. Immunol., 1994, 94, 625-628.
236. Ra, C.; Yasuda, M.; Sagara, H.; Yagita, H.; Okumura, K. The role of adhesion molecules in triggering effector phase of immune responses. Allergy Proc., 1995, 16, 39-41.
237. Zwartz, G.; Chigaev, A.; Foutz, T.; Larson, R.S.; Posner, R.; Sklar, L.A. Relationship between molecular and cellular dissociation rates for VLA-4/VCAM-1 interaction in the absence of shear stress. Biophys. J.; 2004, 86, 1243-1252.
238. Okayama, Y.; Kawakami, T. Development, migration, and survival of mast cells. Immunol. Res., 2006, 34, 97-115.